Hera Biotech has filed a notice of an exempt offering of securities to raise $6 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Hera Biotech is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Somer Baburek played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Hera Biotech
Hera Biotech is developing and commercializing the worlds 1st non-surgical test for definitive diagnosis and staging of endometriosis. Hera Biotech, Inc. was formed to apply advances in biotechnology to address unmet needs in the field of women’s health and specifically, in reproductive medicine. Hera began operations in January of 2020 as a Delaware “C” Corporation with headquarters in San Antonio, TX. Hera’s initial goal is to commercialize the MetriDx, a novel, non-surgical method for the definitive and early diagnosis of endometriosis. Endometriosis is defined as the presence of endometrial glands and stromal-like lesions outside of the uterus.1 Endometriosis affects 10-20% of all women of reproductive age; 7-13 million in the US alone.2,3 Current diagnosis of endometriosis is by visualization during laparoscopic surgery, confirmed by histological pathology, performed under general anesthesia by a surgeon or gynecologist. The surgical methodology suffers from being highly site specific, depending on the experience of the surgeon, failure to detect lesions in ~16% of cases and almost half of all biopsies are negative.4 Alternatively, many physicians choose to diagnose the disease empirically or, without a definitive diagnosis; this results in multiple “trial & error” interventions, increased liability risk and patient frustration. In most cases, patients suffer between 7-12 years with intense pain before a diagnosis is given and interventions are administered, with 68% of women with endometriosis being misdiagnosed with another condition prior to receiving the correct diagnosis.3,4
To learn more about Hera Biotech, visit http://herabiotech.com/
Hera Biotech Linkedin Page: https://www.linkedin.com/company/hera-biotech/
Contact:
Somer Baburek, Chief Executive Officer
210-683-1069
https://www.linkedin.com/in/somerbaburek/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.